scholarly journals Clinical benefit for cryopreservation of single human spermatozoa for ICSI: A systematic review and meta‐analysis

Andrology ◽  
2021 ◽  
Author(s):  
Chuan Huang ◽  
Run‐Xin Gan ◽  
Jian‐Lin Hu ◽  
Feng Liu ◽  
Yan Hong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Benefit ◽  
Meta Analysis ◽  
Human Spermatozoa

scholarly journals Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis

ESMO Open ◽  
2017 ◽  
Vol 2 (4) ◽  
pp. e000225 ◽  
Author(s):  
Sierra Cheng ◽  
Mahin Qureshi ◽  
Eleanor Pullenayegum ◽  
Adam Haynes ◽  
Kelvin KW Chan
Keyword(s):  
Systematic Review ◽  
Clinical Benefit ◽  
Meta Analysis ◽  
Performance Status ◽  
Cancer Therapies ◽  
Excellent Performance

Is There Any Clinical Benefit for Peri-operative Administration of Tranexamic Acid for Patients Undergoing Percutaneous Nephrolithotomy? A Systematic Review and Meta-analysis

2021 ◽  
Vol 22 (12) ◽  
Author(s):  
Panagiotis Kallidonis ◽  
Athanasios Vagionis ◽  
Konstantinos Pagonis ◽  
Angelis Peteinaris ◽  
Amelia Pietropaolo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Tranexamic Acid ◽  
Percutaneous Nephrolithotomy ◽  
Clinical Benefit ◽  
Meta Analysis

scholarly journals THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis

2015 ◽  
Vol 172 (5) ◽  
pp. R215-R225 ◽  
Author(s):  
E N Klein Hesselink ◽  
D Steenvoorden ◽  
E Kapiteijn ◽  
E P Corssmit ◽  
A N A van der Horst-Schrivers ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Clinical Benefit ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Objective Response ◽  
Disease Response ◽  
Hand Foot Syndrome

ContextMany tyrosine kinase inhibitors (TKIs) have been studied in patients with thyroid carcinoma (TC). However, the effect and toxicity of various TKIs in differentiated TC (DTC) and medullary TC (MTC) patients have not been directly compared. The aim of the present systematic review and meta-analysis was to systematically summarize response and toxicity of TKIs in TC patients.MethodsAll major databases were systematically searched for publications on TKIs in TC. Primary endpoint was objective response; secondary endpoints were clinical benefit, percentage TKI dose reduction/discontinuation, hand–foot syndrome, diarrhea, and nausea/vomiting. Meta-analysis was performed using an exact likelihood approach and a logistic regression. Pooled percentages and 95% CIs were reported.ResultsIn total, 22 publications were included. For DTC patients, gefitinib induced no objective responses. Pooled percentage was highest for pazopanib, 49 (95% CI 33–64)%, and was 17 (95% CI 12–24)% for sorafenib. For MTC, gefitinib and imatinib induced no objective responses, whereas sunitinib induced objective response in 43 (95% CI 14–77)%. For vandetanib and cabozantinib, these numbers were 40 (95% CI 34–46)% and 27 (95% CI 22–32)% respectively. Clinical benefit was found in 53 (95% CI 48–59)% of DTC patients on sorafenib, and in 84 (95% CI 79–88)% and 55 (95% CI 49–61)% of MTC patients on vandetanib and cabozantinib respectively. All TKIs were associated with considerable toxicity.ConclusionThe currently studied TKIs show a modest response, while side effects are not negligible. Therefore, we suggest to solely consider TKIs in TC patients with rapid progressive disease, for whom the benefits of treatment outweigh toxicity.

Sign in / Sign up

Export Citation Format

Share Document